Evidence map›Paper›PMID 39825571›Full record

Trial reportJournal of cachexia, sarcopenia and muscle2025

Muscle Loss During First-Line Chemotherapy Impairs Survival in Advanced Pancreatic Cancer Despite Adapted Physical Activity.

Pauline Parent, Frédéric Pigneur, Marc Hilmi, Aurélien Carnot, Marie-Line Garcia Larnicol, Dewi Vernerey, Alain Luciani, Pascal Hammel, Julie Henriques, Cindy Neuzillet and 1 more

Abstract readRandomized Controlled TrialClinical Trial, Phase III
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of cachexia, sarcopenia and muscle, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Pauline ParentDepartment of Medical Oncology, Lille University Hospital, Lille, France.ORCID 0000-0001-6072-7357
Frédéric PigneurDepartment of Radiology, Henri Mondor Hospital, AP-HP, University of Paris Est, UPEC, Créteil, France.
Marc HilmiDepartment of Medical Oncology, Institute Curie, Université Versailles Saint-Quentin, Paris Saclay, Saint-Cloud, France.
Aurélien CarnotDepartment of Medical Oncology, Centre Oscar Lambret, Lille, France.
Marie-Line Garcia LarnicolGERCOR, Paris, France.
Dewi VernereyMethodology and Quality of Life Unit in Oncology, University of Besancon, Besançon, France.
Alain LucianiDepartment of Radiology, Henri Mondor Hospital, AP-HP, University of Paris Est, UPEC, Créteil, France.
Pascal HammelDepartment of Digestive and Medical Oncology, Paul Brousse Hospital, University Paris-Saclay, Villejuif, France.
Julie HenriquesMethodology and Quality of Life Unit in Oncology, University of Besancon, Besançon, France.
Cindy NeuzilletDepartment of Medical Oncology, Institute Curie, Université Versailles Saint-Quentin, Paris Saclay, Saint-Cloud, France.
Anthony TurpinDepartment of Medical Oncology, Lille University Hospital, Lille, France.

Funding

ARCAD FoundationGEFLUC GrantGERCORSANTELYS grant
6 · The paper itself

Abstract

backgroundAdvanced pancreatic ductal adenocarcinoma (aPDAC) is often accompanied by significant muscle mass loss, contributing to poor prognosis. SarcAPACaP, an ancillary study of the GERCOR-APACaP phase III trial, evaluated the role of adapted physical activity (APA) in aPDAC Western patients receiving first-line chemotherapy. The study aimed to assess (1) the potential impact of computed tomography (CT)-quantified muscle mass before and during treatments on health-related quality of life (HRQoL) and overall survival (OS) and (2) the role of APA in mitigating muscle mass loss.

methodsIn the APACaP trial, aPDAC patients with ECOG performance status (PS) 0-2 were randomized 1:1 to usual care including first-line chemotherapy or usual care plus a 16-week home-based APA program. In the SarcAPACaP study, the surface muscular index (SMI) was determined from L3 CT scan slices. Two patient populations were analysed: those with CT scan available at baseline (modified[m] intent-to-treat [ITT]1-W0) and those with CT scans available at both W0 and W16 (mITT2 W0-W16). Low muscle mass was defined by low SMI with SMI < 41 cm

resultsBetween October 2014 and May 2020, 313 patients were prospectively enrolled, with 225 in mITT1 W0 and 128 in mITT2 W0-W16, with 65 assigned to the APA arm. Both groups had similar baseline characteristics with comparable OS and TUDD. A low SMI at W0 was not associated with OS and TUDD of HRQoL in either group. Among mITT2 W0-W16 patients, high muscle mass loss (n = 27) independently predicted OS (p = 0.012) and showed a trend toward negatively affecting TUDD of HRQoL. Notably, APA did not mitigate muscle loss in our study population.

conclusionsLongitudinal muscle mass loss emerged as a predictive factor for both OS and HRQoL in aPDAC patients undergoing chemotherapy, while a low SMI at diagnosis did not provide prognostic value. APA did not impact muscle mass loss in this population.

Indexed as

ExercisePancreatic NeoplasmsAgedFemaleHumansMaleMiddle AgedMuscle, SkeletalQuality of LifeTomography, X-Ray Computedadapted physical activityCT scanmuscular mass losspancreatic cancerquality of lifesarcopenia

Identifiers

PMID39825571
PMCPMC11788588

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.